136
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Dendrocrepidamine, a novel octahydroindolizine alkaloid from the roots of Dendrobium crepidatum

, , , ORCID Icon, , & show all
Pages 1085-1092 | Received 22 Dec 2020, Accepted 24 May 2021, Published online: 15 Jun 2021
 

Abstract

A novel octahydroindolizine alkaloid, named dendrocrepidamine (1) with an unusual 18,19,19′-cyclopropanone-dendrocrepine skeleton, was isolated from the ethanol extract of the roots of Dendrobium crepidatum, along with six known compounds (27). The structure of 1 was elucidated through HR-ESIMS, NMR spectroscopic data and computational calculations. All compounds were examined for their inhibitory effects on nitric oxide (NO) production induced by lipopolysaccharide (LPS) in RAW264.7 cells with IC50 values in the range of 3.04–54.89 µM. In vivo, crepidatin (6) (80, 40 and 10 mg/kg) showed a significant protective effect against LPS-induced acute lung injury (ALI) in mice.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was financially supported by the Ministry of Science and Technology of China under National Key R&D Program (2018YFC1707900), the National Natural Science Foundation (81803391), the Natural Science Foundation of Jiangsu (BK20180828), and the Natural Science Foundation Youth Program of Nanjing University of Chinese Medicine (NZY81803391).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.